Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 3Completed 3Recruiting 2Unknown 1

Sponsor Class

OTHER 4INDUSTRY 3NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Weight Loss 2Cachexia 2Body Weight 2Anorexia 2Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Megestrol Acetate × Clear all
NCT03077698 2022-06-07

An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

Xenetic Biosciences, Inc.

Phase 2 Terminated
25 enrolled 14 charts
Gynecologic

Recurrence, Endometrial Neoplasms

NCT00637728 2016-06-23

Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients

Par Pharmaceutical, Inc.

Phase 3 Terminated
5 enrolled 8 charts
GastrointestinalThoracic

Anorexia, Body Weight, Cachexia, Lung Neoplasms, Pancreatic Neoplasms, Weight Loss

NCT00637806 2016-05-02

Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension

Par Pharmaceutical, Inc.

Phase 3 Terminated
4 enrolled 6 charts

Anorexia, Body Weight, Cachexia, Neoplasms, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡